GW Pharma cannabis drug set to hit market following DEA nod
U.S.-listed shares of GW Pharmaceuticals rose 8 percent on Thursday as its marijuana-based treatment Epidiolex cleared the last hurdle after the Drug Enforcement Administration labeled the drug as having a low abuse potential. (Source: Reuters: Health)
Source: Reuters: Health - September 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Janssen Elects Not to Continue Agreement with Geron for Imetelstat
(Source: Johnson and Johnson)
Source: Johnson and Johnson - September 27, 2018 Category: Pharmaceuticals Source Type: news

Bending The Health Care Curve Toward Personalized Care: By Dr. Harold Paz, EVP & CMO, Aetna
Healthcare, like many other American industries, is moving away from a one-size-fits-all model in favor of highly individualized care that addresses each patient's unique needs. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 27, 2018 Category: Pharmaceuticals Authors: Gary Price, MD, and Tim Norbeck, Contributor Source Type: news

Johnson & Johnson Announces New Collaboration to Advance Novel Vaccine for MERS
(Source: Johnson and Johnson)
Source: Johnson and Johnson - September 27, 2018 Category: Pharmaceuticals Source Type: news

Aiming To Revolutionize Medical Ultrasound, Butterfly Raises $250 Million At A $1.25 Billion Valuation
The flood of cash represents a victory swashbuckling biotech entrepreneur Jonathan Rothberg who aims to change medical imaging with his $2,000 device. Investors include Fidelity, The Bill& Melinda Gates Foundation, and Fosun Pharma. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 27, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Source Type: news

In clinical trials, new antibody therapy controls HIV for months after treatment
Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers in the body, threatening to rise to dangerous levels should a patient forget or forgo treatment. To remain healthy, people infected with HIV must therefore adhere to strict medication regimens, which typically involve ingesting pills every day for the rest of their lives. (Source: World Pharma News)
Source: World Pharma News - September 27, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Abbott Receives CE Mark for First Troponin Test to Help Predict the Chance of Heart Attack in Apparently Healthy Adults Potentially Months to Years in Advance
- Research shows adding Abbott's High Sensitive Troponin-I diagnostic test to doctors' existing standard of care can help more accurately determine a person's chances of a heart attack or other cardiac event potentially months to years in advance (Source: Abbott.com)
Source: Abbott.com - September 26, 2018 Category: Pharmaceuticals Source Type: news

Lawmakers accuse the drug industry of trying to ‘hijack’ opioid bill
As a new bill to address the nation ’s opioid epidemic moves quickly through Congress, pharma industry lobbyists have attempted to include a provision that would lower brand-name drugmakers'discounts to Medicare patients. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 26, 2018 Category: Pharmaceuticals Source Type: news

DePuy Synthes Expands Spine Portfolio with Nerve Assessment Platform Designed to Identify & Avoid Nerves During Spine Surgery
(Source: Johnson and Johnson)
Source: Johnson and Johnson - September 26, 2018 Category: Pharmaceuticals Source Type: news

Drug prices went UP after President Trump declared pharma companies were about to slash them
In May, President Trump announced his plan to drive drug prices down, and said that 'massive' cuts were coming in the next weeks. But an AP report reveals the vast majority rose this summer. (Source: the Mail online | Health)
Source: the Mail online | Health - September 26, 2018 Category: Consumer Health News Source Type: news

Safe and effective prescribing: A new and important initiative from the PhRMA Foundation
Safe and effective prescribing is a critically important part of the equation for successful medical treatment in today ’s health care system. Yet data from the Association of American Colleges cites a lack of sufficient training and resources in safe and effective prescribing in the U.S. medical school curriculum. (Source: The Catalyst)
Source: The Catalyst - September 26, 2018 Category: Pharmaceuticals Tags: PhRMA Foundation Source Type: news

Big Pharma Boosts Drug Prices As Supplies Run Low, Study Reveals
Drug companies display " opportunistic behavior " while pricing products that are in short supply, the authors of a new study allege. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 26, 2018 Category: Pharmaceuticals Authors: Arlene Weintraub, Contributor Source Type: news

Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - September 26, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Watch the recording: Flex it up. How advanced pharma companies can introduce more agile and dynamic teams in sales, marketing and medical
Julian Tompkins, President of Ashfield Commercial and Clinical joined panellists from McKinsey, ALK and GSK for an eyeforpharma debate. To stay at the cutting edge, your sales and... The post Watch the recording: Flex it up. How advanced pharma companies can introduce more agile and dynamic teams in sales, marketing and medical appeared first on Ashfield Healthcare. (Source: Ashfield Healthcare News)
Source: Ashfield Healthcare News - September 26, 2018 Category: Pharmaceuticals Authors: Ashfield Source Type: news

Pre-Filled Syringes & Injectable Drug Devices Europe 2018
16 - 17 January 2019, London, UK. The conference will offer a deep insight into key areas within the field, such as: new technologies and overcoming their hurdles to implementation; connectivity for devices; updates on drug development and the impact on device developments and new regulatory guidelines. The line-up of expert speakers will enable delegates to learn from market leaders on best practices to overcome common industry hurdles. (Source: World Pharma News)
Source: World Pharma News - September 26, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Blockchain Genomics Startup Wants To Make You Money With Your DNA
London-based blockchain startup Genomes.io is on a mission to protect and productize DNA. By sequencing and securely storing full genome sequences using blockchain technology, industries such as pharma and insurance will be able to query an individual ’s DNA data and reimburse those who accept. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 26, 2018 Category: Pharmaceuticals Authors: Gemma Milne, Contributor Source Type: news

Mayo Clinic expands all three sites to meet growing demand for destination care
ROCHESTER, Minn. ? To meet growing patient demand, Mayo Clinic is expanding its destination medical centers in Rochester; Jacksonville, Florida; and Phoenix. The nearly $1 billion investment will enable Mayo to help more patients with serious, complex and rare conditions, and continue to accommodate the research, education and technologies that improve and save lives. ?Every [...] (Source: Mayo Clinic Business News)
Source: Mayo Clinic Business News - September 26, 2018 Category: Pharmaceuticals Source Type: news

Data Ownership Is Having Its Moment
Fear of change is a powerful force. Many believe that if something truly novel is created, something existing must die. It ’s as if innovation is a zero-sum game.Change can be disruptive and expensive, but there are some precious times when change – or rather evolution – can be purely constructive.The marketplace for the data of individual healthcare consumers is broken. It ’s unsustainable, unfriendly and everyone knows that sooner or later it must change. That change can come through lawsuits and legislation or by the healthcare industry proactively embracing a new system design that is a win-win ...
Source: EyeForPharma - September 25, 2018 Category: Pharmaceuticals Authors: Richie Etwaru Source Type: news

One-Year Results from Real-World Study Showed Abbott's Portico ™ Transcatheter Aortic Valve Safely and Successfully Reduced Severe Aortic Stenosis
- Late-breaking data from real-world experience with the first fully repositionable and retrievable valve were consistent with previous results, and support that Portico can be successfully used in various anatomies in a real-world setting (Source: Abbott.com)
Source: Abbott.com - September 25, 2018 Category: Pharmaceuticals Source Type: news

Tax Reform No Shot In Arm For Pharma Deals
Divests are plentiful but mega-deals lag. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 25, 2018 Category: Pharmaceuticals Authors: Mergermarket, Contributor Tags: NYSE:AET NYSE:TEVA NYSE:AGN OTCMKTS:TKPYY NYSE:CI Source Type: news

PhRMA comments in response to request for information on competitive bidding program in Medicare Part B
Yesterday, the Pharmaceutical Research and Manufacturers of America (PhRMA) submittedcomments in response to the recent 2019 Hospital Outpatient Prospective Payment System proposed rule, including the request for information (RFI) regarding the creation of a competitive acquisition program (CAP) in Medicare Part B through the Center for Medicare& Medicaid Innovation (CMMI). In the comments, PhRMA raised a couple key areas for the Administration to consider before moving forward on any CAP proposal, including: (Source: The Catalyst)
Source: The Catalyst - September 25, 2018 Category: Pharmaceuticals Tags: Medicare Part B CMMI Source Type: news

New report shows more than 300 skin disease medicines in development
More than 100 million Americans – one third of the U.S. population – suffer from skin conditions. (Source: The Catalyst)
Source: The Catalyst - September 25, 2018 Category: Pharmaceuticals Tags: Medicines in Development GoBoldly Source Type: news

Roche ’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
Roche today announced positive results from the Phase III IMpower133 study of Tecentriq ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 25, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
Roche today announced positive results from the Phase III IMpower133 study of Tecentriq ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - September 25, 2018 Category: Pharmaceuticals Source Type: news

New drug blocks pancreatic cancer growth in mice, study finds
A newly developed drug can prevent the most common type of pancreatic cancer from growing and spreading in laboratory mice, according to a study led by Cedars-Sinai. The study, published recently in the journal Gastroenterology, also demonstrated in mice that the drug, called Metavert, may prevent patients from developing a resistance to currently used pancreatic cancer chemotherapies. (Source: World Pharma News)
Source: World Pharma News - September 25, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer
AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Toronto, Canada. (Source: World Pharma News)
Source: World Pharma News - September 25, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

BLINCYTO ® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
First Approved Oncology Treatment From Amgen Astellas Joint Venture BLINCYTO is the First-and-Only Approved CD19-Directed CD3 Bispecific T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., Sept. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). BLINCYTO was developed in Japan by Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas Pharma Inc., a pharmaceuti...
Source: Amgen News Release - September 25, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Johnson & Johnson Announces 10-year Initiative to Help End Tuberculosis, the World ’s #1 Infectious Killer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - September 24, 2018 Category: Pharmaceuticals Source Type: news

Ethicon ’s novel skin closure system leads to higher patient and surgeon satisfaction after total knee replacement
(Source: Johnson and Johnson)
Source: Johnson and Johnson - September 24, 2018 Category: Pharmaceuticals Source Type: news

Drug prices rising despite Trump pressure on Big Pharma
President's prediction of "massive" voluntary price cuts by drugmakers is not happening, AP review of brand names shows (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 24, 2018 Category: Consumer Health News Source Type: news

Roche ’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
Roche today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA trials, which showed that entrectinib shrank tumours (objective response rate; ORR) in 77.4% of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
Roche today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA trials, which showed that entrectinib shrank tumours (objective response rate; ORR) in 77.4% of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - September 24, 2018 Category: Pharmaceuticals Source Type: news

Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program
The changes made to Part D in the Bipartisan Budget Act (BBA) that passed in February threaten the program ’s successful competitive structure. While these changes closed the donut hole a year early, they went much further by lowering insurers ’ payment responsibility to just five percent of costs in the donut hole for brand medications. (Source: The Catalyst)
Source: The Catalyst - September 24, 2018 Category: Pharmaceuticals Authors: Juliet Johnson Tags: drug cost Burden on Patients Part D out of pocket costs Source Type: news

DNA islands effective as 'anti-bacterial drones'
Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a threat to safe hospital care, a new study finds. Conducted by researchers from NYU School of Medicine and published online in the journal Nature Biotechnology, the study found that a certain type of bacterial DNA can be engineered to replace disease-causing genes with ones that kill or cripple bacteria. (Source: World Pharma News)
Source: World Pharma News - September 24, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to enhance the development of medical products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry across the country. (Source: World Pharma News)
Source: World Pharma News - September 24, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
Roche announced today the global availability of FoundationOne ®Liquid, a liquid biopsy test. (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
Roche announced today the global availability of FoundationOne ®Liquid, a liquid biopsy test. (Source: Roche Media News)
Source: Roche Media News - September 24, 2018 Category: Pharmaceuticals Source Type: news

Kavanaugh accuser Christine Blasey Ford was a Big Pharma shill for company that makes “morning after” abortion pill
(Natural News) The insane Democratic Left’s main opposition to POTUS Donald Trump’s second Supreme Court nominee, Judge Brett Kavanaugh, is that he may wind up someday being the deciding vote to overturn Roe v. Wade, the 1973 SCOTUS ruling that legalized abortion in all 50 states and enshrined it as a “right” for women. That’s... (Source: NaturalNews.com)
Source: NaturalNews.com - September 23, 2018 Category: Consumer Health News Source Type: news

Landmark Study Shows Treatment with Abbott's MitraClip ® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation
- The COAPT trial met both the primary safety and efficacy endpoints and all secondary endpoints, including reducing all-cause mortality through two years (Source: Abbott.com)
Source: Abbott.com - September 23, 2018 Category: Pharmaceuticals Source Type: news

Alcohol Is Responsible For 5% Of All Deaths Globally, Study Finds
A new World Health Organization report suggests that people around the world are still drinking themselves to death. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 22, 2018 Category: Pharmaceuticals Authors: Alice G. Walton, Contributor Source Type: news

FDA: Here Is The 2019 Strategic Approach To Combat Antimicrobial Resistance
FDA Commissioner Scott Gottlieb outlined these 4 general strategic approaches to address the problems of increasing antimicrobial resistance and a lack of new antibiotics being developed. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 22, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

Pets, If You Are On These Flea And Tick Medications, Beware Of Seizures
The FDA has issued a warning about medications in the isoxazoline class such as Bravecto, Credelio, Nexgard and Simparica. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 22, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

Watch at REAL.video as Robert Scott Bell discusses how Big Pharma is a tool for human sacrifice
(Natural News) What’s the biggest killer of Americans? It’s not illicit drugs, cigarettes, or even terrorism, as the establishment would have you believe. It’s modern medicine, which kills upwards of 786,000 Americans annually. During a recent episode of his show, available for viewing at REAL.video, Robert Scott Bell discusses information presented in an article by... (Source: NaturalNews.com)
Source: NaturalNews.com - September 22, 2018 Category: Consumer Health News Source Type: news

beWellnm will launch its own exchange platform
BeWellnm's board of directors voted unanimously Friday for the New Mexico Health Insurance Exchange to become a state-based exchange, which the organization said will streamline operations and save clients money. Cheryl Gardner, the insurance exchange's CEO, said beWellnm is currently operating with a federal technology platform, which had a price tag of $5.5 million as of this year, with estimates of reaching $10.9 million by 2019 and $14 million by 2020. The organization will look at vendors… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 22, 2018 Category: Pharmaceuticals Authors: Ron Davis Source Type: news

Mukesh Rathi uses digital to give Dr. Reddy ’s a competitive edge
The metric that we use to gauge the success of our digital initiatives is the eventual business benefit that it delivers to the organization, Says Rathi (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 22, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
(Source: Johnson and Johnson)
Source: Johnson and Johnson - September 21, 2018 Category: Pharmaceuticals Source Type: news

Pharma with Duke University roots files to go public
A clinical-stage pharmaceutical firm with Duke University roots has filed paperwork to go public in an $86.3 million offering – one that could mean a windfall for a Triangle investor. PhaseBio Pharmaceuticals, which spun out of Duke University in 2002 and counts Durham's Hatteras Venture Partners as a backer, relocated its headquarters from Durham to Pennsylvania in 2010. Late Friday, the company, which focuses on trea ting rare diseases – particularly in the cardiopulmonary space – filed… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 21, 2018 Category: Biotechnology Authors: Lauren K. Ohnesorge Source Type: news

Pharma with Duke University roots files to go public
A clinical-stage pharmaceutical firm with Duke University roots has filed paperwork to go public in an $86.3 million offering – one that could mean a windfall for a Triangle investor. PhaseBio Pharmaceuticals, which spun out of Duke University in 2002 and counts Durham's Hatteras Venture Partners as a backer, relocated its headquarters from Durham to Pennsylvania in 2010. Late Friday, the company, which focuses on trea ting rare diseases – particularly in the cardiopulmonary space – filed… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 21, 2018 Category: Pharmaceuticals Authors: Lauren K. Ohnesorge Source Type: news